Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

26 search results for igg

filterselect all | reset

Sort by

Order

Suggestions within Pfizer.com

Updates & Statements

Article

Page

People Profiles

Podcast

Press Release

Product

filter select all | reset

Type

Updates & Statements

Article

Page

People Profiles

Podcast

Press Release

Product

Date Range

Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases

ordered multimers of normal human IgG Fc to its receptors. About Gliknik …

Press Release
Science Fact or Science Fiction? Avoiding Peanuts as an Infant Reduces Allergy Risk

encounters that allergen again, it triggers an inflammatory response. "It protective immunoglobulins known as IgG and IgG4. "The LEAP study was a …

Article
BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2

as measured by RBD-binding IgG concentrations and SARS-CoV-2 …

Press Release
FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions

Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of levels at baseline had low IgA, IgG, and IgM levels, respectively, …

Press Release
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARSCoV-2 in Nature

as measured by RBD-binding IgG concentrations and SARS-CoV-2 …

Press Release
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)

antibodies called “immunoglobulins” (IgG) in the blood which help protect …

Press Release
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

(NI) of immunoglobin G (IgG) geometric mean concentrations with predefined serotype-specific IgG concentrations after Dose 3 (two …

Press Release
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

titers and RBD-binding IgG concentrations after the second …

Press Release
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2

adults, which suggest that BNT162b2 triggers the production of neutralizing receptor binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 …

Press Release
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS

adults, which suggest that BNT162b2 triggers the production of neutralizing with prespecified serotype-specific IgG concentrations and IgG Geometric …

Press Release

Page 1
Current page 2
Page 3

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

October 2025

10.13.2025
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
10.09.2025
Pfizer Declares Fourth-Quarter 2025 Dividend
- Financial
- Finance

September 2025

09.30.2025
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
- Corporate
09.25.2025
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
- Research and Pipeline
- Research
09.23.2025
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
- Financial
- Finance
09.22.2025
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
- Corporate
- Research and Pipeline
09.08.2025
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
- Covid-19
- Vaccines

August 2025

08.27.2025
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
- Covid-19
- Vaccines
08.12.2025
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Research and Pipeline
- Medicines
08.05.2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

July 2025

07.25.2025
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
- Vaccines
- Vaccines
07.24.2025
Pfizer Completes Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline
07.10.2025
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
- Research and Pipeline
- Medicines

June 2025

06.26.2025
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
- Prescription Medicines
- Medicines
06.25.2025
Pfizer Declares Third-Quarter 2025 Dividend
- Financial
- Finance
06.25.2025
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
- Financial
- Finance
06.02.2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

May 2025

05.31.2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- Research and Pipeline
- Research
05.30.2025
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
05.22.2025
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- Research and Pipeline
- Medicines
05.19.2025
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline

April 2025

04.29.2025
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
04.26.2025
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Research and Pipeline
04.24.2025
Pfizer Announces 2025 Shareholder Meeting Preliminary Results
04.23.2025
Pfizer Declares Second-Quarter 2025 Dividend
- Financial
- Finance
04.23.2025
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
- Research and Pipeline
04.16.2025
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
- Vaccines
- Vaccines
04.14.2025
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
- Research and Pipeline
- Research
04.10.2025
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
- Corporate
- Finance
04.01.2025
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
- Vaccines
- Vaccines

March 2025

03.18.2025
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
- Financial
- Finance
03.11.2025
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- Research and Pipeline
- Research

February 2025

02.24.2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance
02.13.2025
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
- Prescription Medicines
- Medicines
02.12.2025
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Prescription Medicines
- Medicines
02.10.2025
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- Research and Pipeline
- Medicines
02.04.2025
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
02.03.2025
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
- Prescription Medicines
- Medicines

January 2025

01.28.2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
- Research and Pipeline
01.25.2025
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
01.10.2025
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Research and Pipeline
- Research
01.06.2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

December 2024

12.20.2024
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
12.19.2024
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
- Financial
- Finance
12.17.2024
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
12.12.2024
Pfizer Declares First-Quarter 2025 Dividend
- Financial
- Finance
12.12.2024
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- Prescription Medicines
- Medicines
12.10.2024
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- Financial
- Finance

Page 1
Current page 2
Page 3
Page 4
Page 5

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2026 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube